Guzzi LM, et al. - Researchers focused on the current clinical use of the first FDA-approved test to evaluate risk for acute kidney injury, [TIMP-2 (tissue inhibitor of metalloproteinases-2)]•[IGFBP7 (insulin-like growth factor binding protein 7)]. For this purpose, they organized a panel discussion with the experts knowledgeable on the utility of this test, to know the candidates suitable for testing, how the results are interpreted, and actions need to be taken based on test results. As for use of the [TIMP-2]•[IGFBP7] test, similar practice patterns were seen among clinical experts in Europe and North America. Priority patient populations for biomarker testing were those undergoing major surgery (both cardiac and non-cardiac), those who were hemodynamically unstable, or those with sepsis. Management of nephrotoxic drugs as well as fluids is a priority for cases with a positive test, while “fast-track” protocols should be considered in those with negative results.